TokenPost·
Immix Biopharma Reports $340.9 Million in Cash, Cash Equivalents and Marketable Securities
The company expects the balance at quarter-end to fund operations into mid-2028. Third-quarter operating expenses were $15.9 million.
More news
- TokenPostMattr Posts C$423.4 Million in Q3 Revenue, C$0.43 Non-GAAP EPS
- TokenPostIEH Corporation Posts 69.6% Revenue Growth as Q2 EPS Beats Estimates
- TokenPostNational Vision Cuts 2026 Revenue Outlook While Accelerating Store Growth
- TokenPostLument Finance Trust Reports -$0.13 GAAP EPS, $0.63 Below Estimates
- TokenPostSouthland Holdings Posts $0.62 Diluted Earnings Per Share for Q3 2026
- TokenPostExchange Income Posts C$1.06 Billion in Q3 2026 Revenue, C$1.81 Adjusted EPS